Exploring the Role of Local Therapy and Molecular Markers in Advanced Bladder and Prostate Cancer

Exploring the Role of Local Therapy and Molecular Markers in Advanced Bladder and Prostate Cancer

Introduction:
The field of oncology is constantly evolving, with researchers and clinicians striving to find the most effective treatment strategies for advanced bladder and prostate cancer. At the European Association of Urology (EAU) Annual Congress in 2023, experts engaged in a spirited debate regarding the use of local therapy in patients with oligometastatic disease in bladder cancer. Similarly, the Clinical Utility of Molecular Markers was a topic of discussion at the Advanced Prostate Cancer Consensus Conference (APCCC) in 2019. In this article, we will explore the common points and insights from these two important events, focusing on the potential role of local therapy and the clinical utility of molecular markers in the management of advanced bladder and prostate cancer.

Local Therapy in Oligometastatic Bladder Cancer:
During the EAU Annual Congress, Dr. Bamias advocated for local therapy in patients with oligometastatic disease, while Dr. Necchi favored systemic treatment as the optimal approach. The definition of oligometastasis remains a contentious issue, with the AJCC 7th edition defining it as T4bN0M0, TanyN1-3M0, and TanyNanyM1. Dr. Necchi emphasized the use of "first-line" therapy and highlighted the potential of immunotherapy to significantly improve the prognosis of patients with oligometastatic bladder cancer. On the other hand, Dr. Bamias stressed the importance of personalized diagnosis and treatment strategies, suggesting that local ablation therapy and stereotactic radiation therapy could provide survival benefits in select patients. It is evident that focused clinical and translational research is needed to address the unmet needs in the management of oligometastatic bladder cancer.

Molecular Markers in Advanced Prostate Cancer:
At the APCCC, Dr. De Bono discussed the clinical utility of molecular markers in advanced prostate cancer. He highlighted the urgent need for assay analytic validation and clinical qualification, as well as the emerging role of molecular stratification in the management of metastatic castration-resistant prostate cancer (mCRPC). Several biomarkers were identified, including AR biomarkers, PI3K/AKT and PTEN aberrations, transformation biomarkers, and DNA repair defects. DNA repair defects, found in a small percentage of mCRPC patients, are often associated with high tumor-infiltrating lymphocytes (TILs). Furthermore, PTEN loss and PI3K/AKT aberrations have been linked to resistance to abiraterone and poor prognosis. Dr. De Bono emphasized the need for further data to ascertain the utility of these molecular markers and the importance of patient selection for PSMA targeting agents.

Connecting the Dots:
While the discussions at the EAU Congress and APCCC focused on different types of urological cancers, they share common themes and insights. Both events highlighted the need for personalized treatment approaches in advanced cancer, taking into account individual patient characteristics and molecular profiles. Furthermore, they emphasized the importance of clinical and translational research to improve patient outcomes.

Actionable Advice:

1. Emphasize the need for clinical and translational research: To address the unmet needs in the management of oligometastatic bladder cancer and advanced prostate cancer, it is crucial to invest in focused research efforts. This will help identify potential therapeutic targets and improve patient selection for specific treatment modalities.

2. Incorporate molecular markers into clinical practice: The clinical utility of molecular markers in advanced prostate cancer is becoming increasingly evident. Integrating these biomarkers into routine clinical practice can aid in treatment decision-making, allowing for more personalized and targeted approaches.

3. Consider a multidisciplinary approach: Managing advanced bladder and prostate cancer requires a multidisciplinary team approach, involving urologists, medical oncologists, radiation oncologists, and pathologists. Collaborative decision-making and shared expertise can lead to improved patient outcomes and better treatment strategies.

Conclusion:
The discussions at the EAU Congress and APCCC shed light on the potential role of local therapy and molecular markers in the management of advanced bladder and prostate cancer. While systemic treatment remains the cornerstone of therapy, there is growing evidence supporting the use of local therapy in select patients with oligometastatic disease. Similarly, molecular markers have the potential to guide treatment decisions and improve patient outcomes in advanced prostate cancer. To harness the full potential of these approaches, further research and collaboration among healthcare professionals are essential. By adopting a personalized, multidisciplinary approach, we can strive towards better outcomes for patients with advanced bladder and prostate cancer.